摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3S-tert-butoxycarbonylamino-5-hydroxypentanoic acid methyl ester | 886039-50-5

中文名称
——
中文别名
——
英文名称
3S-tert-butoxycarbonylamino-5-hydroxypentanoic acid methyl ester
英文别名
methyl (3S)-5-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
3S-tert-butoxycarbonylamino-5-hydroxypentanoic acid methyl ester化学式
CAS
886039-50-5
化学式
C11H21NO5
mdl
——
分子量
247.291
InChiKey
KBCKDGSSQGHHMK-QMMMGPOBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    375.8±37.0 °C(Predicted)
  • 密度:
    1.104±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    17
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    84.9
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUND HAVING READ-THROUGH ACTIVITY
    申请人:THE UNIVERSITY OF TOKYO
    公开号:US20140364642A1
    公开(公告)日:2014-12-11
    [Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound. [Solution] A compound represented by the following general formula (1): and a pharmaceutical composition containing this compound.
    一种具有读穿活性的新化合物以及包含该化合物的用于治疗无义突变型疾病的药物。 一种由以下一般式(1)表示的化合物: 以及含有该化合物的药物组合物。
  • New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations
    作者:Keisuke Hamada、Noriko Omura、Akihiro Taguchi、Alireza Baradaran-Heravi、Masaya Kotake、Misaki Arai、Kentaro Takayama、Atsuhiko Taniguchi、Michel Roberge、Yoshio Hayashi
    DOI:10.1021/acsmedchemlett.9b00273
    日期:2019.10.10
    We report a novel negamycin derivative TCP-1109 (13x) which serves as a potent readthrough drug candidate against nonsense-associated diseases. We previously demonstrated that TCP-112 (7), a nor-compound of native 3-epi-deoxynegmaycin, showed a higher readthrough activity than (+)-negamycin. In the present study, we performed a structure-activity relationship (SAR) study of compound 7 focused on its 3-amino group in an effort to develop a more potent readthrough compound. Introduction of a variety of natural or unnatural amino acids to the 3-amino group gave us the more potent derivative 13x which has about four times higher readthrough activity than 7 in a cell-based assay using a premature termination codon of TGA derived from Duchenne muscular dystrophy. The activity was dose-dependent and relatively selective for TGA. However, the activities for TAG and TAA were also higher than those of (+)-negamycin and 7. Moreover, compound 13x showed significant cell-based readthrough activity for several nonsense mutations derived from other nonsense-associated diseases. It is suggested that 13x has the potential to be a readthrough drug useful for the treatment of many kinds of nonsense-associated diseases.
  • US9371274B2
    申请人:——
    公开号:US9371274B2
    公开(公告)日:2016-06-21
  • An Efficient Enantioselective Approach to Cyclic β-Amino Acid Derivatives via Olefin Metathesis Reactions
    作者:Giordano Lesma、Bruno Danieli、Alessandro Sacchetti、Alessandra Silvani
    DOI:10.1021/jo060062t
    日期:2006.4.1
    The asymmetric synthesis of polyfunctionalized piperidine- and pyrrolidine-based scaffolds, specifically designed for the preparation of cyclic, conformationally constrained β-amino acids, is realized combining a biocatalytic access to a versatile chiral building block with a wide range of transformations based on olefin metathesis.
    专为制备环状,构象受限的β-氨基酸而设计的多官能化哌啶和吡咯烷基支架的不对称合成,是通过生物催化获得通用的手性结构单元以及基于烯烃复分解的多种转化方法而实现的。
查看更多